Location: Boston,MA, USA
Senior Research Associate – Biophysics SPR & FRET
Location: Boston
Monte Rosa Therapeutics is seeking a passionate Senior Research Associate with the experience to implement and run biochemical and biophysics assays. This is an exciting opportunity to join a team responsible for the biochemical and biophysical characterization of novel small molecule glue-based degraders to support Monte Rosa's growing pipeline. The successful candidate will have proven bench level expertise in establishing and performing a range of biochemical and biophysics assays to screen and characterize small molecule compounds and elucidate mechanism of action. The candidate should exhibit excellent communication and collaborative skills for working on cross-functional teams, as well as demonstrate a high degree of independence and organization.
Principal Duties and Responsibilities
Qualifications
Interested candidates should forward CV and cover letter to ...@monterosatx.com or apply on line www.monterosatx.com
About Monte Rosa
Monte Rosa Therapeutics is a clinical-stage biotechnology company developing highly selective molecular glue degrader (MGD) medicines for patients living with serious diseases in the areas of oncology, autoimmune and inflammatory diseases, and more. MGDs are small molecule protein degraders that have the potential to treat many diseases that other modalities, including other degraders, cannot. Monte Rosa's QuEEN™ (Quantitative and Engineered Elimination of Neosubstrates) discovery engine combines AI-guided chemistry, diverse chemical libraries, structural biology and proteomics to identify degradable protein targets and rationally design MGDs with unprecedented selectivity. The QuEEN discovery engine enables access to a wide-ranging and differentiated target space of well-validated biology across multiple therapeutic areas. Monte Rosa has developed the industry's leading pipeline of MGDs, which spans oncology, autoimmune and inflammatory disease and beyond, and has a strategic collaboration with Roche to discover and develop MGDs against targets in cancer and neurological diseases previously considered impossible to drug. For more information, visit www.monterosatx.com.